Multi-site manufacturing is the norm for commercial products, and the operating recipe rarely survives a site transfer unchanged. Equipment geometry, batch size, and local utilities push parameters and set points apart, leaving regulatory and CMC teams to decide how much divergence a filing can absorb — and whether the difference is a notification, a prior-approval supplement, or a variation that reopens the process validation package.
The analysis below traces how FDA and EMA each frame parameter differences between sites, the ICH vocabulary both rely on, the comparability evidence expected to show the product is unaffected, and the site-specific process validation each agency requires. It also covers where the two regimes diverge on filing mechanics and post-approval change flexibility.
Want Rhizome's help on your own question? Try it for free.
Process parameters and set points across manufacturing sites: how FDA and EMA judge the difference
When the same product is made at more than one site, or a process is moved from one site to another, the operating recipe rarely transfers unchanged. Equipment geometry, batch size, utilities, and local qualification realities push process parameters and set points apart. Both FDA and EMA start from the same premise: what has to stay the same is the product and its critical quality attributes (CQAs), not the numeric values of the parameters used to make it. A difference in a process parameter or set point is acceptable if, and only if, two things are shown. First, the change does not adversely affect the product (comparability). Second, the process as run at each site is itself validated (process performance/validation at that site). The two agencies frame these questions with closely aligned science, built on the same ICH backbone, but they differ in the regulatory mechanics of how the change is filed and what flexibility is available.
The unit of comparison is the product, not the parameter
ICH Q8 and Q11 supply the vocabulary both agencies use. A critical process parameter (CPP) is a parameter whose variability affects a CQA and therefore must be monitored or controlled. A proven acceptable range (PAR) is a characterised range for a single parameter within which, holding other parameters constant, the process yields material meeting quality criteria. A design space is the multidimensional combination of input variables and process parameters demonstrated to assure quality 5072. This framing matters for multi-site work because it moves the regulatory question away from "are the numbers identical?" toward "does the resulting product remain within its quality expectations?"
The most consequential rule follows directly: operating within an approved design space is not considered a change, while moving outside it is a change that normally triggers a post-approval procedure 5056. A design space can even be made site-independent, but only where process robustness is demonstrated and site-specific factors (materials, equipment, personnel, utilities, environment) are considered in depth; regional post-approval requirements for site changes still apply regardless 52. Site, scale, or equipment changes can also trigger design-space verification, guided by a risk assessment of the change's potential impact 48. In other words, a well-constructed design space can absorb some parameter and set-point differences between sites, but it does not exempt a manufacturer from local process validation or from the applicable site-change filing.
One caveat worth flagging for authors of validation protocols: in the ICH text, "set point" and "normal operating range" are used but not formally defined the way CPP and PAR are 5072. Both concepts are treated as operating targets sitting inside the qualified/characterised ranges, and verification studies are ordinarily run at the normal operating set points 227.
FDA: site-specific PPQ plus a risk-based change filing
FDA treats the two questions (is the process validated here, and is the product comparable) through two distinct instruments.
Validation at the site. FDA's process validation lifecycle makes process performance qualification (PPQ) explicitly site- and commercial-process-specific: it combines the qualified facility, utilities, equipment, trained personnel, the routine commercial process, procedures, and components to make commercial batches 103. FDA expects the site's facility, utilities, and equipment to be qualified first (installed to design specification and able to operate across the anticipated operating ranges under representative load) 104; a written PPQ protocol specifying operating parameters, processing limits, tests, acceptance criteria, sampling, and data evaluation, with sampling and statistical scrutiny beyond routine production 105; PPQ batches made under normal commercial conditions at that site 113; a PPQ report evaluating all data and departures 102; and continued process verification to hold the validated state afterward 102101. FDA is explicit that validation is not merely showing that set points or PARs exist; it is documented evidence that the process, as run with that site's actual facilities and people, reproducibly delivers acceptable product 106103113. Notably, changes to operating ranges or set points during continued verification require documented change planning, rationale, an implementation plan, and quality-unit approval before implementation, with further qualification work if quality impact is possible 101.
Filing the change. A move or process change to an approved product is a post-approval CMC change. The applicant must assess the effect before distributing post-change product and demonstrate, through validation and/or laboratory or clinical studies, that identity, strength, quality, purity, and potency are not adversely affected 948393. FDA assigns a reporting category by risk: Prior Approval Supplement (PAS) for major potential effect (approval before distribution), CBE-30 or in defined cases CBE-0 for moderate effect, and Annual Report for minimal effect 839978. Where multiple changes are bundled, the highest-risk change, and potentially the cumulative impact, drives the category 88. For biologics, FDA's examples classify certain process changes as PAS, including changes in upstream culture conditions such as time, temperature, or pH outside the approved BLA parameters, or media composition changes 90. A site change is judged on its risk to process performance and product quality, not simply because the address changed 93, and the supporting package must demonstrate comparability of the relevant pre- and post-change intermediates, drug substance, and/or drug product 93, commensurate with product/process complexity and risk 98. Successful completion of Stage 2 process validation is required in addition to meeting the reporting-category requirements before commercial distribution 79.
Comparability protocols. FDA's comparability protocol (CP), which FDA equates with the ICH Q12 post-approval change management protocol, is a prospectively written plan that names the change, the tests and analytical procedures, and the acceptance criteria that must be met to conclude no adverse effect 87789298. Submitted in the original application or a PAS, an approved CP lets FDA pre-agree the scientific plan; if all acceptance criteria are met, FDA may grant a reduced reporting category for the defined change, so a move that would otherwise be a PAS may proceed as, for example, a CBE-30 789199. A CP is well suited to a discrete, well-understood facility/equipment/process change (including implementing one change across multiple facilities under one license, or a lab relocation) 8980, and poorly suited to broad, open-ended plans or changes whose effect predefined criteria cannot bound 89. If acceptance criteria are not met, product made with the change must not be distributed and the applicant discusses the path forward with FDA 79.
EMA: validate every site, classify the change as a variation
Validation at the site. EMA's process validation guideline requires validation to cover all marketed strengths and every proposed manufacturing site, performed under GMP, with site-held data available for inspection 229. Bracketing may be justified for strengths, batch sizes, or pack sizes, but it does not remove the requirement to cover all sites 229. For finished products requiring production-scale data (such as biologicals), data should come from consecutive production-scale batches, normally at least three unless justified; one or two may suffice with supportive pilot-scale, technology-transfer, and prior-experience data 221. EMA does not prescribe a universal batch number for biotech active substances either; the number depends on process complexity, variability, and deviation history 220. Crucially for multi-site classification, EMA expects a case-by-case justification per site (experience with the same/similar product, development knowledge and batches at each site, and the site's GMP-compliance history) to treat a traditionally validated process as "standard" rather than "non-standard" 229226.
EMA's treatment of PARs and set points is unusually explicit. For biotech active substances, process-evaluation studies must show, for each relevant step, that operation within the proposed input ranges produces outputs meeting predefined acceptance criteria, and this evidence supports the claimed PARs 227220. Prior or platform knowledge can support operating ranges or input set points only when shown representative of the proposed commercial process, and verification studies are generally run at the normal operating set points 227220. Continuous process verification (CPV) is available as an alternative or supplement to traditional validation, and a hybrid approach (traditional for some steps, CPV for others) is permitted provided the dossier states which approach applies to each step 221215. Where a design space is used, a change in the normal operating range may require design-space verification, especially where parameters are not demonstrated to be scale-independent 223.
EU GMP Annex 15. Annex 15 anchors the GMP expectations. Process validation is documented evidence that a process operated within established parameters reproducibly produces product meeting specifications 195, and it explicitly covers initial validation, validation after modifications, site transfers, and ongoing process verification 196. New-product validation must cover all intended marketed strengths and sites 196. For a transfer between sites, or within a site, the number of validation batches may be reduced through a justified bracketing approach that leverages existing product knowledge, including the prior validation content 196. Qualification (URS, DQ, IQ, OQ, PQ) is required for the receiving site's equipment and utilities, with OQ confirming operating limits and worst-case conditions and PQ demonstrating reproducible performance across the intended operating range 188186. Annex 15 does not set universal CPP values or a fixed batch number; the manufacturer must establish product- and process-specific controls and predefined acceptance criteria in the protocol, supported by risk management 192200. Change management under GMP requires QRM to determine what testing, requalification, revalidation, or regulatory communication is needed before a facility, equipment, material, process, or technical-transfer change is implemented 157.
Filing the change. The EU variations framework classifies changes by potential impact: Type IA (minimal/none), Type IB (default for changes that are neither IA, Type II, nor an extension), and Type II (may significantly affect quality, safety, or efficacy) 169164. A substantial manufacturing-process change to the finished product or active substance that may significantly affect quality, safety, or efficacy is Type II, and any change to the manufacturing process or sites of a biological active substance is Type II 161. Administrative name/address changes are IA only where the physical location and all operations are unchanged 172. For a minor finished-product process change to qualify as Type IA, a demanding set of conditions must all hold, including no change to the impurity profile or physico-chemical properties, the change touching only non-critical process parameters (or specific low-risk dosage forms), unchanged manufacturing principle and steps, unchanged in-process controls and specifications, and a product identical in every respect of quality, safety, and efficacy 166. The Type IA support package requires a direct comparison of the approved and proposed processes, comparative batch-analysis data for at least two batches by each process, dissolution or particle-size comparisons as relevant, and started stability studies 166167. Active-substance site changes are principally a comparability package: comparative tabulated batch data for at least two pilot-scale batches (three for biologicals unless justified), GMP-compliance evidence for the proposed site, and analytical-procedure transfer protocols with pre-defined acceptance criteria per EudraLex Volume 4 Chapter 6 174.
Comparability: the shared scientific core (ICH Q5E)
For biological products, both agencies run on ICH Q5E, and the alignment is close to complete. Q5E requires a risk- and science-based comparability exercise proving that pre- and post-change product remains comparable in quality, safety, and efficacy; "manufacturing process" expressly includes changes in facilities and equipment that could affect critical processing parameters, and the guideline applies to contract manufacturers provided the products can be directly compared 137131. The standard is highly similar, not identical: observed differences are acceptable where prior and product knowledge predict no adverse effect on safety or efficacy 131139.
The expected evidence is a direct, integrated pre-/post-change comparison against predefined criteria, drawing on routine batch data, in-process results, process validation data, characterisation, and stability 135; testing at the stage(s) best able to detect the change, potentially spanning intermediates, drug substance, and drug product 135; physicochemical and biological characterisation including higher-order structure, activity, purity, and impurities 132133; analytical methods capable of detecting plausible differences, reassessed and supplemented as needed 134132; stability including stress studies 134136; and evaluation of critical control points, in-process controls, operating limits, and hold times, with the modified process providing at least equivalent control 134136. The decision logic is a staircase: if quality studies show highly similar attributes, comparability can be concluded from quality alone and no nonclinical/clinical studies are warranted 131135; if the analytical package cannot rule out relevant differences, add characterisation and, if needed, nonclinical/clinical bridging 135; if differences are observed but scientifically justified as having no adverse impact, the products can still be comparable 135; and if differences could affect safety or efficacy and cannot be resolved by more testing, nonclinical and/or clinical bridging (PK, PD, efficacy, safety, immunogenicity) should follow 135139.
FDA's and EMA's own comparability guidance restate this same staircase. FDA calls for a side-by-side comparison showing the post-change product remains highly similar, escalating to nonclinical/clinical bridging only where quality evidence is insufficient, and it scales the exercise to what moves: a bulk drug-substance site change generally calls for extensive analytical plus functional testing, whereas a filling-site change may sometimes be supported by comparative release and stability data 134521. EMA describes the same stepwise, product-driven approach, with the explicit point that clinical data are not a way to justify substantial quality differences but only to address slight, already-characterised differences 140141149155.
On process parameters specifically, both agencies converge: the focus is the resulting product and its CQAs, not identity of the parameters. Differences in process parameters are acceptable where the comparability exercise shows the product remains highly similar with no adverse quality consequence, investigated at the process stage(s) most likely to reveal an effect 140155153. Where methods cannot bound a difference in set-point methodology, that is treated as a data gap to be closed by characterisation, not by assertion.
Lifecycle mechanics: ICH Q12 established conditions and PACMPs
ICH Q12 supplies the forward-looking machinery both agencies are adopting. Established Conditions (ECs) are the elements needed to assure quality for which a regulatory communication is required if changed; a process parameter is an EC if it is a CPP or its quality impact cannot reasonably be excluded 3446. Q12 then assigns a reporting category by risk (high risk generally prior approval, moderate/low notification, non-EC changes not reported), with the Product Lifecycle Management document holding the ECs and their categories 4632. The depth of the EC set depends on approach: a minimal parameter-based approach designates many parameters as ECs, while enhanced or performance-based approaches (supported by data-rich manufacturing, models, or PAT) can focus ECs on the most important inputs or on process outputs, and can support a lower reporting category, for example moving a CPP change from prior approval to notification 464745.
The post-approval change management protocol (PACMP) is Q12's counterpart to FDA's comparability protocol: a protocol agreed in advance defining the planned change, how it will be verified, the acceptance criteria, and the proposed reporting category, executed in two steps (protocol approval, then execution and reporting) 2627. Q12 expressly supports PACMPs for manufacturing-site changes, including a single alternative site and broader protocols spanning multiple products and sites where the risk profile is similar 2829. For a small-molecule alternative drug-substance site, the illustrative acceptance criterion is comparative analysis of three consecutive batches from the alternative site meeting the approved specification, with stability initiated, and conditions including acceptable GMP status, similar/equivalent equipment, completed technology transfer and process qualification, and no change to synthetic route, control strategy, impurity profile, or specifications 2938. For a biotech drug-substance transfer, the package covers hazard identification, side-by-side analytical characterisation, comparable process-performance attributes and impurities, planned process validation, degradation studies, a recipient-site risk assessment, and validation/stability plans, while excluding opportunistic yield-improving process changes 3644. Throughout, the MAH remains responsible for meeting the jurisdiction's GMP, inspection, and licensing requirements before implementing 26.
The evidence package, in practice
For a difference in process parameters or set points between sites for the same product, a submission that satisfies both agencies generally assembles, proportionate to risk:
- A clear description and direct comparison of the approved and proposed process, identifying which parameters and set points differ and why (equipment, scale, utilities), and where each sits relative to CPP status, PARs, and any design space 9316650.
- A risk assessment (ICH Q9-based) categorising the change and, for EU, mapping it to a variation type; for FDA, to a reporting category 4616183. Where a design space or wider PAR is claimed to cover the difference, the supporting robustness and site-specific evidence 5248.
- Site qualification and process validation/PPQ at the receiving site: qualified facility/utilities/equipment, a protocol with predefined operating parameters and acceptance criteria, consecutive commercial-scale batches (bracketing permitted for transfers with prior knowledge), and a validation report, followed by continued/ongoing process verification 103105113196192.
- A comparability package scaled to what moves: side-by-side analytical, physicochemical, and (for biologics) functional/biological characterisation of the relevant intermediates, drug substance, and/or drug product, plus stability, against predefined criteria, escalating to nonclinical/clinical bridging only where residual uncertainty remains 931351401.
- Validated (or transferred and re-verified) analytical methods, with analytical-transfer protocols and pre-defined acceptance criteria 92174.
- GMP-compliance evidence for the receiving site and confirmation the quality unit approves implementation only once acceptance criteria are met 9317495.
Where the two regimes converge and diverge
The scientific expectations are, for practical purposes, harmonised. Both agencies judge the difference by its effect on the product's CQAs rather than by numeric identity of parameters; both require the receiving site's process to be independently validated; both run comparability on the ICH Q5E staircase for biologics; and both are moving toward Q12-style established conditions and pre-agreed change protocols to earn regulatory flexibility.
The differences are procedural. FDA channels the change through the PAS/CBE-30/CBE-0/Annual Report hierarchy and offers the comparability protocol to secure a reduced reporting category in advance 839978. EMA channels it through the Type IA/IB/II variations classification, with detailed conditions and prescribed comparative data per change category, and treats "covers all sites" as a validation requirement in its own right 169164229. FDA's PPQ language is emphatically site-specific; EMA's Annex 15 and process validation guideline reach the same destination but give more explicit permission to reduce validation-batch numbers on transfer through justified bracketing that leverages the originating site's data 113196. For biological active-substance changes and sites, the EU classification is firmly Type II 161, which parallels FDA's tendency to place equivalent biologic process changes in the PAS tier 90. A program that documents parameter and set-point differences against CQAs, validates the process at each site, and builds the comparability evidence to the Q5E standard will meet both regimes; the remaining work is fitting that evidence into each agency's filing vehicle and timing.